Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

SAMe Is Effective In Preventing Formation Of Primary Liver Cancer In Rats
A new study investigated the effectiveness of S-adenosylmethionine (SAMe) in the prevention and treatment of hepatocellular carcinoma (HCC) or primary liver cancer. SAMe, a widely available nutritional supplement, with little known side effects, was found to be effective in preventing the formation of HCC in rats. However, high enough levels of SAMe were not attainable to successfully treat established HCC. The findings are available in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases.
diet pills
Boehringer Ingelheim To Present New Phase II Clinical Data On Two Lead Oncology Compounds At ASCO 2009
Boehringer Ingelheim will present new data on the company"s two lead oncology compounds, BIBW 2992* and BIBF 1120** at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company announced today. Two studies in the LUX-Lung clinical development programme for BIBW 2992 and a Phase II study of BIBF 1120 in ovarian cancer patients will be presented.
News of the day
Erythropoietin Boosts Brainpower
Healthy young mice treated with erythropoietin show lasting improved performance in learning and other higher brain functions. Researchers writing in the open access journal BMC Biology tested the cognitive effects of the growth factor, finding that it improved the sequential learning and memory components of a complex long-term cognitive task.
Sexual Health

Metabolic Disease Drug Discovery Conference: Monday September 21, 2009

on both Clinical and Business Fronts 3:00 Shaping Business Development Through Collaboration Ventures -- Identifying what are the requirements to establish early stage research collaborations -- Extending knowledge gathering beyond existing in-house capabilities -- Expanding the value of a partnership beyond a single deal -- Outsourcing lead finding and early development to partnering companies Dr. Dennis Kim, SVP, Metabolic Diseases, Orexigen Therapeutics Inc 3:45 Scientific Licensing Strategy & Process: Focus on Metabolic Disease Interests -- Outlining Merck"s scientific licensing strategy and review process -- Providing a review of the partnering process, including initiation and negotiation processes -- Identifying what Merck looks for in a potential therapeutic candidate -- Discussing specific licensing priorities for the metabolic diseases area Dr. Lauren Shearman, Associate Director, Scientific Liaison External Scientific Affairs, Merck 4:30 End of Conference IDGA

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009